Abstract:Systemic, non-viral siRNA delivery for cancer treatment is mainly achieved via condensation by cationic materials (e.g., lipids and cationic polymers), which nevertheless, suffers from poor serum stability, non-specific tissue interaction, and unsatisfactory membrane activity against efficient in vivo gene knockdown. Here, we report the design of a metastable, cancer-targeting siRNA delivery system based on two functional polymers, PVBLG-8, a cationic, helical cell-penetrating polypeptide, and poly(l-glutamic acid) (PLG), an anionic random-coiled polypeptide. PVBLG-8 with rigid, linear structure showed weak siRNA condensation capability, and PLG with flexible chains was incorporated as a stabilizer which provided sufficient molecular entanglement with PVBLG-8 to encapsulate the siRNA within the polymeric network. The obtained PVBLG-8/siRNA/PLG nanoparticles (PSP NPs) with positive charges were sequentially coated with additional amount of PLG, which reversed the surface charge from positive to negative to yield the metastable PVBLG-8/siRNA/PLG@PLG (PSPP) NPs. The PSPP NPs featured desired serum stability during circulation to enhance tumor accumulation via the enhanced permeability and retention (EPR) effect. Upon acidification in the tumor extracellular microenvironment and intracellular endosomes, the partial protonation of PLG on PSPP NPs surface would lead to dissociation of PLG coating from NPs, exposure of the highly membrane-active PVBLG-8, and surface charge reversal from negative to positive, which subsequently promoted tumor penetration, selective cancer cell internalization, and efficient endolysosomal escape. When siRNA against epidermal growth factor receptor (EGFR) was encapsulated, the PSPP NPs showed excellent tumor penetration capability, tumor cell uptake level, EGFR silencing efficiency, and tumor growth inhibition efficacy in U-87 MG glioblastoma tumor spheroids in vitro and in xenograft tumor-bearing mice in vivo, outperforming the PSP NPs and several commercial reagents such as Lipofectamine 2000 and poly(l-lysine) (PLL). This study therefore demonstrates a facile and unique design approach of metastable and charge reversal NPs, which overcomes multiple biological barriers against systemic siRNA delivery toward anti-cancer treatment.

A Versatile Platform for the Tumor‐Targeted Intracellular Delivery of Peptides, Proteins, and siRNA

Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform

Potent Protein Delivery into Mammalian Cells Via a Supercharged Polypeptide.

Novel Chitosan Derivatives with Reversible Cationization and Hydrophobicization for Tumor Cytoplasm-Specific Burst Co-delivery of Sirna and Chemotherapeutics

Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA

Enhancing Sirna-Based Cancer Therapy Using a New Ph-Responsive Activatable Cell-Penetrating Peptide-Modified Liposomal System

Endocytosis‐independent and Cancer‐selective Cytosolic Protein Delivery via Reversible Tagging with LAT1 substrate

Spatial distribution control of antimicrobial peptides through a novel polymeric carrier for safe and efficient cancer treatment

Tumor Targeting and Microenvironment-Responsive Multifunctional Fusion Protein for Pro-Apoptotic Peptide Delivery

Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo

A high hydrophobic moment arginine-rich peptide screened by a machine learning algorithm enhanced ADC antitumor activity

A polymeric nanocarrier with a tumor acidity-activatable arginine-rich (R9) peptide for enhanced drug delivery.

Simple and Efficient Targeted Intracellular Protein Delivery with Self‐Assembled Nanovehicles for Effective Cancer Therapy

Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route.

Zwitterionic Nanoparticles Constructed with Well-Defined Reduction-Responsive Shell and Ph-Sensitive Core for “spatiotemporally Pinpointed” Drug Delivery

Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles

Enhanced Intracellular and Intranuclear Drug Delivery Mediated by Biomimetic Peptide SVS-1 for Anticancer Therapy

Protein-drug Conjugate Programmed by Ph-Reversible Linker for Tumor Hypoxia Relief and Enhanced Cancer Combination Therapy.

Dual-Responsive Polymer Micelles for Target-Cell-Specific Anticancer Drug Delivery

Charge-guided Masking of a Membrane-Destabilizing Peptide Enables Efficient Endosomal Escape for Targeted Intracellular Delivery of Proteins

Charge-Selective Delivery of Proteins Using Mesoporous Silica Nanoparticles Fused with Lipid Bilayers.